15 results on '"Papa, Sophie"'
Search Results
2. Setting the scene – a future 'epidemic' of immune-related adverse events in association with checkpoint inhibitor therapy.
- Author
-
Bermudez, Maria V and Papa, Sophie
- Subjects
- *
TUMOR treatment , *TUMORS , *DRUG development - Abstract
Cancer immune therapy with checkpoint inhibitors (CPIs) has changed the landscape of treatment for a growing number of indications. These drugs are associated with a specific mechanism of action that has profound implications for both immunology and inflammatory disease. This article looks to set the scene covering the history of CPI therapy to date and outlining the likely future developments. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Dynamic imaging for CAR-T-cell therapy.
- Author
-
Emami-Shahri, Nia and Papa, Sophie
- Subjects
- *
ANTIGEN receptors , *IN vivo studies , *T cells , *CELLULAR therapy , *PHOTON emission , *COMPUTED tomography - Abstract
Chimaeric antigen receptor (CAR) therapy is entering the mainstream for the treatment of CD19+ cancers. As is does we learn more about resistance to therapy and the role, risks and management of toxicity. In solid tumour CAR therapy research the route to the clinic is less smooth with a wealth of challenges facing translating this, potentially hugely valuable, therapeutic option for patients. As we strive to understand our successes, and navigate the challenges, having a clear understanding of how adoptively transferred CAR-T-cells behave in vivo and in human trials is invaluable. Harnessing reporter gene imaging to enable detection and tracking of small numbers of CAR-T-cells after adoptive transfer is one way by which we can accomplish this. The compatibility of certain reporter gene systems with tracers available routinely in the clinic makes this approach highly useful for future appraisal of CAR-T-cell success in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
4. Proceedings of the inaugural Dark Genome Symposium: November 2022.
- Author
-
Boeke, Jef D., Burns, Kathleen H., Chiappinelli, Katherine B., Classon, Marie, Coffin, John M., DeCarvalho, Daniel D., Dukes, Joseph D., Greenbaum, Benjamin, Kassiotis, George, Knutson, Sarah K., Levine, Arnold J., Nath, Avindra, Papa, Sophie, Rios, Daniel, Sedivy, John, and Ting, David T.
- Subjects
- *
BIOTECHNOLOGY industries , *GENOMES , *CONFERENCES & conventions , *PUBLIC meetings , *RESEARCH personnel - Abstract
In November 2022 the first Dark Genome Symposium was held in Boston, USA. The meeting was hosted by Rome Therapeutics and Enara Bio, two biotechnology companies working on translating our growing understanding of this vast genetic landscape into therapies for human disease. The spirit and ambition of the meeting was one of shared knowledge, looking to strengthen the network of researchers engaged in the field. The meeting opened with a welcome from Rosana Kapeller and Kevin Pojasek followed by a first session of field defining talks from key academics in the space. A series of panels, bringing together academia and industry views, were then convened covering a wide range of pertinent topics. Finally, Richard Young and David Ting gave their views on the future direction and promise for patient impact inherent in the growing understanding of the Dark Genome. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Development of PSMA-specific immunotherapy for prostate cancer with PIN4 gene-modified T cells.
- Author
-
Papa, Sophie, Emami-Shahri, Nia, Zhe Liu, Petrausch, Ulf, Mullen, Gregory, Spicer, James, and Maher, John
- Subjects
- *
IMMUNOTHERAPY , *T cells , *FATTY liver - Abstract
An abstract of the article "Development of PSMA-specific Immunotherapy for Prostate Cancer With PIN4 Gene-modified T Cells," by Sophie Papa, Zhe Liu, and Gregory Mullen is presented.
- Published
- 2014
- Full Text
- View/download PDF
6. Safe delivery of systemic anti‐cancer treatment for skin cancers during the COVID‐19 pandemic.
- Author
-
Monroy‐Iglesias, Maria Jose, Hadi, Hajer, Russell, Beth, Moss, Charlotte, Flanders, Lucy, Dolly, Saoirse, Papa, Sophie, and Van Hemelrijck, Mieke
- Subjects
- *
SKIN cancer , *COVID-19 pandemic , *MOHS surgery , *MEDICAL personnel , *CANCER treatment , *COVID-19 , *EARLY warning score - Abstract
Safe delivery of systemic anti-cancer treatment for skin cancers during the COVID-19 pandemic However, patients undergoing targeted treatment were already being seen less often, in comparison with other SACT patients, before the start of the COVID-19 pandemic. The COVID-19 pandemic has had a profound impact on healthcare services worldwide due to the redeployment of staff and suspension of many scheduled medical and surgical activities.[1] In the context of skin malignancies, treatment regimens have been modified to decrease the need for hospital visits. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
7. Immune checkpoint inhibitor‐related cholangiopathy: Novel clinicopathological description of a multi‐centre cohort.
- Author
-
Berry, Philip, Kotha, Sreelakshmi, Zen, Yoh, Papa, Sophie, El Menabawey, Tareq, Webster, George, Joshi, Deepak, and Heneghan, Michael
- Subjects
- *
IMMUNE checkpoint proteins , *IPILIMUMAB , *BILE ducts , *CEREBRAL amyloid angiopathy , *IMMUNE checkpoint inhibitors , *CLINICAL pathology , *LIVER biopsy , *CHOLANGITIS - Abstract
Background and aims: Cholestatic liver dysfunction is common in immune‐related hepatitis (irH) during treatment with immune checkpoint inhibitors (CPI) for malignancy. We investigated the spectrum of bile duct injury and associated natural history in this cohort. Method: Clinical, laboratory, radiological and histopathological data in patients with evidence of bile duct injury during CPI treatment from 2018 to 2020 was collected in three tertiary hospitals. Results: In this study, ten patients with confirmed bile duct disease were identified. Pembrolizumab was most commonly implicated (8/10). Median CPI cycles prior to bile duct injury was 6. Median alanine aminotransferase and alkaline phosphatase were 225 U/L and 1549 U/L respectively. Clinical jaundice was seen in 6/10 and radiological evidence of bile duct pathology in 8/10. Of five patients, who had liver biopsy, three cases (including two cases with normal MRCP) showed primary sclerosing cholangitis (PSC) like changes with periductal fibrosis. All patients were treated first‐line with prednisolone following cessation of CPI, three with mycophenolate mofetil and one with tacrolimus, with clinical response in four patients. Five patients died after a mean follow‐up of 27 weeks; cause of death was primarily related to progression of malignancy. Conclusion: Within this heterogeneous cohort, we identified that CPI‐related cholangiopathy responded poorly to immunosuppression and potentially progressed to bile duct loss. Thorough radiological and histological assessment is recommended, as identification of the cholangiopathy‐associated phenotype may permit more informed advice regarding prognosis. Further data is required to determine detailed immunological characterisation in order to identify individuals at an increased risk of developing cholangiopathy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. A rapidly expanding cutaneous tumour in the context of a Janus kinase inhibitor agent following allogeneic stem cell transplant.
- Author
-
Davies, Anna, Salisbury, Jon, Mehra, Varun, Papa, Sophie, and Basu, Tanya
- Subjects
- *
STEM cell transplantation , *KINASE inhibitors , *MERKEL cell carcinoma , *TUMORS , *GRAFT versus host disease , *IMMUNE checkpoint inhibitors - Published
- 2022
- Full Text
- View/download PDF
9. CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models.
- Author
-
Cheung, Anthony, Chenoweth, Alicia M., Quist, Jelmar, Sow, Heng Sheng, Malaktou, Christina, Ferro, Riccardo, Hoffmann, Ricarda M., Osborn, Gabriel, Sachouli, Eirini, French, Elise, Marlow, Rebecca, Lacy, Katie E., Papa, Sophie, Grigoriadis, Anita, and Karagiannis, Sophia N.
- Subjects
- *
BIOLOGICAL models , *PROTEINS , *GENE expression profiling , *BREAST tumors , *IMMUNOTHERAPY , *ADIPOSE tissues - Abstract
Simple Summary: The cyclin E/CDK2 complex may present a promising target axis for the treatment of triple-negative breast cancers (TNBC); however, therapeutically relevant doses of CDK2 inhibitors have been associated with toxicities. Here, we report that the suboptimal dosing of the CDK 2, 7 and 9 inhibitor SNS-032 reduced the viability of TNBC cells and upregulated the checkpoint ligand PD-L1 expression in surviving cancer cells in vitro and in human orthotopic MDA-MB-231 TNBC xenografts grown in immunodeficient mice. Moreover, in immunodeficient, TNBC xenograft-bearing mice engrafted with human immune cells, SNS-032 treatment was associated with the infiltration of CD45+ human immune cells in tumors. In these orthotopic MDA-MB-231 TNBC-bearing mice, suboptimal SNS-032 doses given sequentially ahead of dosing with the anti-PD-L1 antibody avelumab significantly restricted tumor growth compared with monotherapy. These findings suggest that surviving cancer cells following suboptimal CDK inhibitor treatment may be responsive to checkpoint immunotherapy. Triple-negative breast cancers (TNBC) expressing PD-L1 qualify for checkpoint inhibitor immunotherapy. Cyclin E/CDK2 is a potential target axis in TNBC; however, small-molecule drugs at efficacious doses may be associated with toxicity, and treatment alongside immunotherapy requires investigation. We evaluated CDK inhibition at suboptimal levels and its anti-tumor and immunomodulatory effects. Transcriptomic analyses of primary breast cancers confirmed higher cyclin E/CDK2 expression in TNBC compared with non-TNBC. Out of the three CDK2-targeting inhibitors tested, the CDK 2, 7 and 9 inhibitor SNS-032 was the most potent in reducing TNBC cell viability and exerted cytotoxicity against all eight TNBC cell lines evaluated in vitro. Suboptimal SNS-032 dosing elevated cell surface PD-L1 expression in surviving TNBC cells. In mice engrafted with human immune cells and challenged with human MDA-MB-231 TNBC xenografts in mammary fat pads, suboptimal SNS-032 dosing partially restricted tumor growth, enhanced the tumor infiltration of human CD45+ immune cells and elevated cell surface PD-L1 expression in surviving cancer cells. In tumor-bearing mice engrafted with human immune cells, the anti-PD-L1 antibody avelumab, given sequentially following suboptimal SNS-032 dosing, reduced tumor growth compared with SNS-032 alone or with avelumab without prior SNS-032 priming. CDK inhibition at suboptimal doses promotes immune cell recruitment to tumors, PD-L1 expression by surviving TNBC cells and may complement immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London.
- Author
-
Russell, Beth, Moss, Charlotte L., Shah, Vallari, Ko, Thinzar Ko, Palmer, Kieran, Sylva, Rushan, George, Gincy, Monroy-Iglesias, Maria J., Patten, Piers, Ceesay, Muhammed Mansour, Benjamin, Reuben, Potter, Victoria, Pagliuca, Antonio, Papa, Sophie, Irshad, Sheeba, Ross, Paul, Spicer, James, Kordasti, Shahram, Crawley, Danielle, and Wylie, Harriet
- Abstract
Background: Using an updated dataset with more patients and extended follow-up, we further established cancer patient characteristics associated with COVID-19 death. Methods: Data on all cancer patients with a positive reverse transcription-polymerase chain reaction swab for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) at Guy's Cancer Centre and King's College Hospital between 29 February and 31 July 2020 was used. Cox proportional hazards regression was performed to identify which factors were associated with COVID-19 mortality. Results: Three hundred and six SARS-CoV-2-positive cancer patients were included. Seventy-one had mild/moderate and 29% had severe COVID-19. Seventy-two patients died of COVID-19 (24%), of whom 35 died <7 days. Male sex [hazard ratio (HR): 1.97 (95% confidence interval (CI): 1.15–3.38)], Asian ethnicity [3.42 (1. 59–7.35)], haematological cancer [2.03 (1.16–3.56)] and a cancer diagnosis for >2–5 years [2.81 (1.41–5.59)] or ≥5 years were associated with an increased mortality. Age >60 years and raised C-reactive protein (CRP) were also associated with COVID-19 death. Haematological cancer, a longer-established cancer diagnosis, dyspnoea at diagnosis and raised CRP were indicative of early COVID-19-related death in cancer patients (<7 days from diagnosis). Conclusions: Findings further substantiate evidence for increased risk of COVID-19 mortality for male and Asian cancer patients, and those with haematological malignancies or a cancer diagnosis >2 years. These factors should be accounted for when making clinical decisions for cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London.
- Author
-
Russell, Beth, Moss, Charlotte L, Shah, Vallari, Ko, Thinzar Ko, Palmer, Kieran, Sylva, Rushan, George, Gincy, Monroy-Iglesias, Maria J, Patten, Piers, Ceesay, Muhammed Mansour, Benjamin, Reuben, Potter, Victoria, Pagliuca, Antonio, Papa, Sophie, Irshad, Sheeba, Ross, Paul, Spicer, James, Kordasti, Shahram, Crawley, Danielle, and Wylie, Harriet
- Abstract
Background: Using an updated dataset with more patients and extended follow-up, we further established cancer patient characteristics associated with COVID-19 death.Methods: Data on all cancer patients with a positive reverse transcription-polymerase chain reaction swab for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) at Guy's Cancer Centre and King's College Hospital between 29 February and 31 July 2020 was used. Cox proportional hazards regression was performed to identify which factors were associated with COVID-19 mortality.Results: Three hundred and six SARS-CoV-2-positive cancer patients were included. Seventy-one had mild/moderate and 29% had severe COVID-19. Seventy-two patients died of COVID-19 (24%), of whom 35 died <7 days. Male sex [hazard ratio (HR): 1.97 (95% confidence interval (CI): 1.15-3.38)], Asian ethnicity [3.42 (1. 59-7.35)], haematological cancer [2.03 (1.16-3.56)] and a cancer diagnosis for >2-5 years [2.81 (1.41-5.59)] or ≥5 years were associated with an increased mortality. Age >60 years and raised C-reactive protein (CRP) were also associated with COVID-19 death. Haematological cancer, a longer-established cancer diagnosis, dyspnoea at diagnosis and raised CRP were indicative of early COVID-19-related death in cancer patients (<7 days from diagnosis).Conclusions: Findings further substantiate evidence for increased risk of COVID-19 mortality for male and Asian cancer patients, and those with haematological malignancies or a cancer diagnosis >2 years. These factors should be accounted for when making clinical decisions for cancer patients. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
12. The threat of triple M and autoimmune overlap syndromes with immune checkpoint inhibitors - A series of case reports.
- Author
-
Masood, Ammara, Mootoo, Amanda, Maghsoudlou, Panayiotis, D'Cruz, David, Srikandarajah, Krishnie, Harries, Mark, Hart, Nicholas, Papa, Sophie, and Spicer, James
- Subjects
- *
IMMUNE checkpoint inhibitors , *SYNDROMES - Published
- 2023
- Full Text
- View/download PDF
13. Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expressing CAR T-Cells.
- Author
-
van Schalkwyk, May C. I., van der Stegen, Sjoukje J. C., Bosshard-Carter, Leticia, Graves, Helen, Papa, Sophie, Parente-Pereira, Ana C., Farzaneh, Farzin, Fisher, Christopher D., Hope, Andrew, Adami, Antonella, and Maher, John
- Subjects
- *
MANUFACTURING processes , *CYTOKINES , *HEAD & neck cancer , *CURRENT good manufacturing practices , *AUTOMOBILES , *T cells - Abstract
Adoptive cancer immunotherapy using chimeric antigen receptor (CAR) engineered T-cells holds great promise, although several obstacles hinder the efficient generation of cell products under good manufacturing practice (GMP). Patients are often immune compromised, rendering it challenging to produce sufficient numbers of gene-modified cells. Manufacturing protocols are labour intensive and frequently involve one or more open processing steps, leading to increased risk of contamination. We set out to develop a simplified process to generate autologous gamma retrovirus-transduced T-cells for clinical evaluation in patients with head and neck cancer. T-cells were engineered to co-express a panErbB-specific CAR (T1E28z) and a chimeric cytokine receptor (4αβ) that permits their selective expansion in response to interleukin (IL)-4. Using peripheral blood as starting material, sterile culture procedures were conducted in gas-permeable bags under static conditions. Pre-aliquoted medium and cytokines, bespoke connector devices and sterile welding/sealing were used to maximise the use of closed manufacturing steps. Reproducible IL-4-dependent expansion and enrichment of CAR-engineered T-cells under GMP was achieved, both from patients and healthy donors. We also describe the development and approach taken to validate a panel of monitoring and critical release assays, which provide objective data on cell product quality. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients.
- Author
-
Russell, Beth, Moss, Charlotte L., Palmer, Kieran, Sylva, Rushan, D'Souza, Andrea, Wylie, Harriet, Haire, Anna, Cahill, Fidelma, Steel, Renee, Hoyes, Angela, Wilson, Isabelle, Macneil, Alyson, Shifa, Belul, Monroy-Iglesias, Maria J, Papa, Sophie, Irshad, Sheeba, Ross, Paul, Spicer, James, Kordasti, Shahram, and Crawley, Danielle
- Subjects
- *
COVID-19 , *CONFIDENCE intervals , *BLACK people , *RACE , *CANCER patients , *RISK assessment , *SOCIOECONOMIC factors , *SEX distribution , *SEVERITY of illness index , *COMPARATIVE studies , *DESCRIPTIVE statistics , *HEMATOLOGIC malignancies , *LOGISTIC regression analysis , *ODDS ratio , *ETHNIC groups - Abstract
Simple Summary: The COVID-19 pandemic has had a detrimental impact on cancer patients globally. Whilst there are several studies looking at the potential risk factors for COVID-19 disease and related death, most of these include non-cancerous patients as the COVID-19 negative comparator group, meaning it is difficult to draw hard conclusions as to the implications for cancer patients. In our study, we utilized data from over 2000 cancer patients from a large tertiary Cancer Centre in London. In summary, our study found that patients who are male, of Black or Asian ethnicity, or with a hematological malignancy are at an increased risk of COVID-19. The use of cancer patients as the COVID-19 negative comparator group is a major advantage to the study as it means we can better understand the true impact of COVID-19 on cancer patients and identify which factors pose the biggest risk to their likelihood of infection with SARS-CoV2. Very few studies investigating COVID-19 in cancer patients have included cancer patients as controls. We aimed to identify factors associated with the risk of testing positive for SARS CoV2 infection in a cohort of cancer patients. We analyzed data from all cancer patients swabbed for COVID-19 between 1st March and 31st July 2020 at Guy's Cancer Centre. We conducted logistic regression analyses to identify which factors were associated with a positive COVID-19 test. Results: Of the 2152 patients tested for COVID-19, 190 (9%) tested positive. Male sex, black ethnicity, and hematological cancer type were positively associated with risk of COVID-19 (OR = 1.85, 95%CI:1.37–2.51; OR = 1.93, 95%CI:1.31–2.84; OR = 2.29, 95%CI:1.45–3.62, respectively) as compared to females, white ethnicity, or solid cancer type, respectively. Male, Asian ethnicity, and hematological cancer type were associated with an increased risk of severe COVID-19 (OR = 3.12, 95%CI:1.58–6.14; OR = 2.97, 95%CI:1.00–8.93; OR = 2.43, 95%CI:1.00–5.90, respectively). This study is one of the first to compare the risk of COVID-19 incidence and severity in cancer patients when including cancer patients as controls. Results from this study have echoed those of previous reports, that patients who are male, of black or Asian ethnicity, or with a hematological malignancy are at an increased risk of COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Utilizing Immunocytokines for Cancer Therapy.
- Author
-
Runbeck, Erin, Crescioli, Silvia, Karagiannis, Sophia N., and Papa, Sophie
- Subjects
- *
CANCER treatment , *CHIMERIC proteins , *CYTOKINES , *CLINICAL trials , *IMMUNOTECHNOLOGY - Abstract
Cytokine therapy for cancer has indicated efficacy in certain diseases but is generally accompanied by severe toxicity. The field of antibody–cytokine fusion proteins (immunocytokines) arose to target these effector molecules to the tumor environment in order to expand the therapeutic window of cytokine therapy. Pre-clinical evidence has shown the increased efficacy and decreased toxicity of various immunocytokines when compared to their cognate unconjugated cytokine. These anti-tumor properties are markedly enhanced when combined with other treatments such as chemotherapy, radiotherapy, and checkpoint inhibitor antibodies. Clinical trials that have continued to explore the potential of these biologics for cancer therapy have been conducted. This review covers the in vitro, in vivo, and clinical evidence for the application of immunocytokines in immuno-oncology. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.